CA2948287A1 - Formulations and methods for vaginal delivery of antiprogestins - Google Patents

Formulations and methods for vaginal delivery of antiprogestins Download PDF

Info

Publication number
CA2948287A1
CA2948287A1 CA2948287A CA2948287A CA2948287A1 CA 2948287 A1 CA2948287 A1 CA 2948287A1 CA 2948287 A CA2948287 A CA 2948287A CA 2948287 A CA2948287 A CA 2948287A CA 2948287 A1 CA2948287 A1 CA 2948287A1
Authority
CA
Canada
Prior art keywords
pharmaceutical formulation
capsule
cdb
pullulan
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2948287A
Other languages
English (en)
French (fr)
Inventor
Joseph S. Podolski
Kuang Hsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Pharmaceuticals International Ltd
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of CA2948287A1 publication Critical patent/CA2948287A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2948287A 2014-05-05 2015-04-22 Formulations and methods for vaginal delivery of antiprogestins Abandoned CA2948287A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461988766P 2014-05-05 2014-05-05
US61/988,766 2014-05-05
PCT/US2015/027122 WO2015171319A1 (en) 2014-05-05 2015-04-22 Formulations and methods for vaginal delivery of antiprogestins

Publications (1)

Publication Number Publication Date
CA2948287A1 true CA2948287A1 (en) 2015-11-12

Family

ID=54392846

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2948287A Abandoned CA2948287A1 (en) 2014-05-05 2015-04-22 Formulations and methods for vaginal delivery of antiprogestins

Country Status (9)

Country Link
US (3) US10064815B2 (enExample)
EP (1) EP3139908A4 (enExample)
JP (2) JP6591447B2 (enExample)
CN (2) CN106232107B (enExample)
AU (1) AU2015256473B2 (enExample)
CA (1) CA2948287A1 (enExample)
IL (1) IL248621B (enExample)
MX (2) MX384159B (enExample)
WO (1) WO2015171319A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20250979T1 (hr) * 2017-04-14 2025-10-24 Capsugel Belgium Nv Pululan kapsule
US10857151B1 (en) 2020-02-21 2020-12-08 Villya LLC Treatment of female genital schistosomiasis
US20220047506A1 (en) 2020-08-12 2022-02-17 Villya LLC Praziquantel Formulations
WO2024158694A1 (en) 2023-01-23 2024-08-02 Villya LLC Compositions and methods for improving the solubility of erectile dysfunction therapeutics
EP4417192A1 (en) * 2023-02-17 2024-08-21 meliodys medical UG Medical device, kit, method, and anti-inflammatory substance

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070516A1 (en) 1997-10-28 2005-03-31 Vivus Inc. As-needed administration of an androgenic agent to enhance female desire and responsiveness
JP2005507874A (ja) * 2001-08-29 2005-03-24 ユーエムディー， インコーポレイテッド 癌治療のための化学療法剤及び膜流出システム阻害剤の経膣送達
US7417013B2 (en) * 2002-05-01 2008-08-26 Mcneil-Ppc, Inc. Warming and nonirritating lubricant compositions and method of comparing irritation
EP1593376A1 (en) * 2004-05-04 2005-11-09 Warner-Lambert Company LLC Improved pullulan capsules
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
EP2144601A4 (en) * 2007-04-05 2012-10-10 Univ Kansas RAPID DISSOLVING PHARMACEUTICAL COMPOSITIONS COMPRISING PULLULANE
KR101662186B1 (ko) * 2007-11-02 2016-10-04 애크럭스 디디에스 피티와이 리미티드 경피 전달 시스템
MX2012010327A (es) * 2010-03-22 2012-11-16 Repros Therapeutics Inc Composiciones y metodos para la administracion no toxica de antiprogestinas.
UA113283C2 (xx) * 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
EP2782584B1 (en) * 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
CA2872644A1 (en) * 2012-05-31 2013-12-05 Allergan Pharmaceuticals International Limited Formulations and methods for vaginal delivery of antiprogestins

Also Published As

Publication number Publication date
AU2015256473A1 (en) 2016-11-17
MX2016014256A (es) 2017-02-06
JP6796693B2 (ja) 2020-12-09
CN111840246A (zh) 2020-10-30
EP3139908A4 (en) 2018-05-16
IL248621B (en) 2020-09-30
EP3139908A1 (en) 2017-03-15
US10064815B2 (en) 2018-09-04
US20180325810A1 (en) 2018-11-15
MX384159B (es) 2025-03-14
IL248621A0 (en) 2017-01-31
JP6591447B2 (ja) 2019-10-16
AU2015256473B2 (en) 2018-07-12
HK1232125A1 (zh) 2018-01-05
CN106232107B (zh) 2020-06-05
US20200222315A1 (en) 2020-07-16
US10555900B2 (en) 2020-02-11
CN106232107A (zh) 2016-12-14
WO2015171319A1 (en) 2015-11-12
MX2020005921A (es) 2020-08-20
JP2019194271A (ja) 2019-11-07
US20170181965A1 (en) 2017-06-29
JP2017514851A (ja) 2017-06-08

Similar Documents

Publication Publication Date Title
AU2013267359B2 (en) Formulations and methods for vaginal delivery of antiprogestins
US20200222315A1 (en) Formulations and methods for vaginal delivery of antiprogestins
JP6397402B2 (ja) 膣内挿入用可溶性エストラジオールカプセル
TWI336623B (en) Pharmaceutical formulation for contraception and hormone-replacement therapy
JP2021098710A (ja) エステトロール成分を含有する口腔内崩壊性投与単位
JP2001523639A (ja) プロゲストゲン−抗プロゲストゲンレジメン
HK40040572A (en) Formulations and methods for vaginal delivery of antiprogestins
WO2010007629A1 (en) A kit comprising anti-emetic and oral contraceptive
HK1232125B (en) Formulations and methods for vaginal delivery of antiprogestins
HK1206622B (en) Formulations and methods for vaginal delivery of antiprogestins
WO2018106914A1 (en) Oral pharmaceutical compositions comprising an unmicronized selective progesterone receptor as active agent

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200307

FZDE Discontinued

Effective date: 20220906